Zoetis (NYSE:ZTS) Hits New 1-Year Low – What’s Next?

Zoetis Inc. (NYSE:ZTS) shares hit a new 52-week low during mid-day trading on Wednesday. The stock traded as low as $69.52 and last traded at $69.7640, with a volume of 2517368 shares changing hands. The stock had previously closed at $70.30.

Analyst Ratings Changes

Several analysts have recently commented on the stock. BNP Paribas Exane reduced their price objective on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research report on Tuesday, August 11th. William Blair reiterated a “market perform” rating on shares of Zoetis in a research report on Thursday, August 6th. Piper Sandler reduced their price target on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a report on Monday, August 10th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Zoetis in a research note on Wednesday, September 9th. Finally, Morgan Stanley set a $85.00 price objective on shares of Zoetis in a report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Hold” and a consensus target price of $101.08.

Zoetis Trading Down 0.8%

The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The company has a market capitalization of $28.83 billion, a P/E ratio of 11.49, a P/E/G ratio of 1.67 and a beta of 0.73. The firm’s 50-day moving average price is $74.70 and its 200 day moving average price is $87.21.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter last year, the firm earned $1.76 EPS. The firm’s revenue for the quarter was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 6.2 earnings per share for the current year.

Hedge Funds Weigh In On Zoetis

Hedge funds have recently modified their holdings of the company. Physician Wealth Advisors Inc. boosted its position in Zoetis by 17.4% during the first quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock worth $73,000 after purchasing an additional 91 shares during the period. Brown Lisle Cummings Inc. grew its position in shares of Zoetis by 6.3% during the 1st quarter. Brown Lisle Cummings Inc. now owns 1,621 shares of the company’s stock valued at $192,000 after purchasing an additional 96 shares in the last quarter. Lipe & Dalton increased its holdings in shares of Zoetis by 2.2% in the first quarter. Lipe & Dalton now owns 4,698 shares of the company’s stock worth $555,000 after purchasing an additional 102 shares during the period. Riverwater Partners LLC raised its position in shares of Zoetis by 3.6% in the fourth quarter. Riverwater Partners LLC now owns 2,949 shares of the company’s stock worth $371,000 after buying an additional 103 shares in the last quarter. Finally, Root Financial Partners LLC boosted its stake in Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after buying an additional 103 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostics and other products for pets and livestock. Its portfolio is designed to help prevent and treat disease, improve animal health and support veterinary care.

The company serves the companion animal market with products for dogs, cats and other pets, including parasiticides, vaccines, dermatology treatments and pain-management therapies. Zoetis also provides animal health products for cattle, swine, poultry, fish and other livestock, along with diagnostic instruments, tests and services used by veterinarians and producers.

Zoetis was established as an independent public company in 2013 after being separated from Pfizer, which had operated the business as Pfizer Animal Health.